{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:28:06Z","timestamp":1789694886982,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.pcad.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T11:30:08Z","timestamp":1597145408000},"page":"662-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Special Article - The management of resistant hypertension: A 2020 update"],"prefix":"10.1016","volume":"63","author":[{"given":"Robert M.","family":"Carey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2020.08.001_bb0005","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation and management, A Scientific Statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0010","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","article-title":"Measurement of blood pressure in humans: a Scientific Statement from the American Heart Association","volume":"73","author":"Muntner","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0015","first-page":"e13","article-title":"A guideline for the prevention, detection, evaluation and management of high blood pressure. A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/HYPERTENSIONAHA.111.00690","article-title":"Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements","volume":"62","author":"Mancia","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.113.02741","article-title":"On behalf of the International Database on Home blood pressure in relation to Cardiovascular Outcome (IDHOCO)","volume":"63","author":"Stergiou","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0030","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jacc.2016.08.035","article-title":"IDACO Investigators., The cardiovascular risk of white-coat hypertension","volume":"68","author":"Franklin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension","volume":"68","author":"Berra","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/jhh.2015.38","article-title":"Non-adherence to antihypertensive medications is very common among resistant hypertensives: results of a directly observed therapy clinic","volume":"30","author":"Hameed","year":"2016","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0045","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijcard.2016.06.263","article-title":"Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients","volume":"220","author":"Schultz","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HJH.0000000000001502","article-title":"Medication adherence among patients with apparent treatment resistant hypertension: systematic review and meta-analysis","volume":"35","author":"Durand","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/jhh.2017.48","article-title":"Factors associated with antihypertensive medication nonadherence: a systematic review","volume":"31","author":"van der Laan","year":"2017","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","article-title":"Prevalence of apparent treatment resistant-hypertension in the United States","volume":"73","author":"Carey","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0065","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.119.13512","article-title":"Outcome-driven thresholds for ambulatory blood pressure based on the new American College of Cardiology\/American Heart Association classification of hypertension","volume":"74","author":"Cheng","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0070","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.ajkd.2013.11.016","article-title":"Incident ESRD and treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study","volume":"63","author":"Tanner","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.pcad.2020.08.001_bb0075","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/ki.2015.142","article-title":"Comparable risk of renal, cardiovascular, and mortality by outcome4s in controlled, uncontrolled resistant and nonresistant hypertension","volume":"88","author":"Sim","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.pcad.2020.08.001_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant hypertension","volume":"75","author":"Jaffe","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Int Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis and treatment. An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pcad.2020.08.001_bb0095","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"38","author":"Neuman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for prevention of cardiovascular events in obstructive sleep apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0105","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ahj.2015.08.006","article-title":"Lifestyle modification for resistant hypertension: the TRIUMPH randomized clinical trial","volume":"170","author":"Blumenthal","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2020.08.001_bb0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jch.12049","article-title":"Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of the obesity society and the American Society of Hypertension","volume":"15","author":"Landsberg","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pcad.2020.08.001_bb0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2020.08.001_bb0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0125","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized trial of dietary sodium restriction in CKD","volume":"34","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0130","doi-asserted-by":"crossref","first-page":"e004473","DOI":"10.1161\/JAHA.112.004473","article-title":"Exercise training for blood pressure: a systematic review and meta-analysis","volume":"2","author":"Comelissen","year":"2013","journal-title":"JAHA"},{"key":"10.1016\/j.pcad.2020.08.001_bb0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/HYPERTENSIONAHA.112.197780","article-title":"Aerobic exercise reduces blood pressure in resistant hypertension","volume":"60","author":"Dimco","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0140","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MBP.0000000000000000","article-title":"Effects of short-term heated water-based exercise training on systemic blood pressure in patients with resistant hypertension: a pilot study","volume":"18","author":"Guimaraes","year":"2013","journal-title":"Blood Press Monit"},{"key":"10.1016\/j.pcad.2020.08.001_bb0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000505895","article-title":"Improved sleep quality improves blood pressure control among patients with chronic kidney disease: a pilot study","volume":"51","author":"Ali","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":"Effects of the angiotensin receptor blocker azilsartan medoximil versus Olmesartan and valsartan on ambulatory and clinic blood pressure in patients with Stages 1 and 2 hypertension","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":"The comparative effects of azilsartan medoximil and olmesartan on ambulatory and clinic blood pressure","volume":"13","author":"Bakris","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pcad.2020.08.001_bb0160","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/jhh.2013.6","article-title":"Antihypertensive efficacy of angiotensin receptor blocker azilsartan medoximil compared with angiotensin converting enzyme inhibitor Ramipril","volume":"27","author":"Bonner","year":"2013","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1161\/HYPERTENSIONAHA.112.192096","article-title":"The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension","volume":"60","author":"Daugherty","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0170","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Int Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0175","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/HYPERTENSIONAHA.120.14782","article-title":"Prognostic importance of on-treatment clinic and ambulatory blood pressures in resistant hypertension","volume":"75","author":"Cardoso","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0180","first-page":"1130","article-title":"Diuretics for hypertension: a review and update","volume":"29","author":"Roush","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/fca.14.83","article-title":"Evidence-based diuretics: focus on chlorthalidone and indapamide","volume":"11","author":"DiNicolantonio","year":"2015","journal-title":"Future Cardiol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0190","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":"Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0195","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1524-6175.2005.04451.x","article-title":"Are chlorthalidone and hydrochlorothiazide equivalent blood pressure lowering medications?","volume":"7","author":"Khosla","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.pcad.2020.08.001_bb0200","doi-asserted-by":"crossref","first-page":"1229.e1","DOI":"10.1016\/j.amjmed.2012.05.023","article-title":"Antihypertensive efficacy of hydrochlorothiazide vs. chlorthalidone combined with azilsartan medoximil","volume":"125","author":"Bakris","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.pcad.2020.08.001_bb0205","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jamainternmed.2019.7454","article-title":"Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension","volume":"150","author":"Hripcsak","year":"2020","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0210","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000358603","article-title":"Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study","volume":"39","author":"Agarwal","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0215","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0220","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Capman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0225","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","article-title":"Body mass index predicts 24-hr urinary aldosterone levels in patients with resistant hypertension","volume":"68","author":"Dudenbostel","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2020.08.001_bb0230","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0235","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0240","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol and doxazosin to determine optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.08.001_bb0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone and amiloride: the PATHWAY-2 mechanisms sub-studies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0250","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0255","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pcad.2020.08.001_bb0260","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomized, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.08.001_bb0265","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2020.08.001_bb0270","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: first global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.pcad.2020.08.001_bb0275","article-title":"Pharmacological profile of KBP-5074, a novel non-steroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"3","author":"Chow","year":"2017","journal-title":"J. Drug Dev."},{"key":"10.1016\/j.pcad.2020.08.001_bb0280","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/eurheartj\/ehy808","article-title":"Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET\/TRANSCEND trials","volume":"41","author":"Bohm","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2020.08.001_bb0285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1524-6175.2004.03585.x","article-title":"Minoxidil: an underused vasodilator for resistant or severe hypertension","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.pcad.2020.08.001_bb0290","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment resistant hypertension (the SIMPLICITY-2 Trial): a randomized controlled trial","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2020.08.001_bb0295","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.112.000949","article-title":"Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension","volume":"128","author":"Mahfoud","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.08.001_bb0300","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2020.08.001_bb0305","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2020.08.001_bb0310","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicenter, randomized, sham-controlled trial","volume":"27","author":"B\u00f6hm","year":"2020","journal-title":"Lancet"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020301535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062020301535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:17:46Z","timestamp":1758500266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062020301535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0033062020301535"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2020.08.001","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Special Article - The management of resistant hypertension: A 2020 update","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}